Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides

Makoto Sugaya, Yoshiki Tokura, Toshihisa Hamada, Ryoji Tsuboi, Yoichi Moroi, Takeshi Nakahara, Masahiro Amano, Syuichi Ishida, Daisuke Watanabe, Mamori Tani, Hironobu Ihn, Jun Aoi, Keiji Iwatsuki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A multisite, open-label, non-randomized, single-arm phase II study was conducted to evaluate the efficacy and safety profiles of interferon-γ in Japanese patients diagnosed with stage IA-IIIA mycosis fungoides (MF). Interferon-γ was administrated i.v. to 15 patients at a dose of 2 million Japan reference units once daily over 5 days a week for the first 4 weeks, followed by subsequent intermittent injection. The primary efficacy end-point was the overall skin response during the study as assessed according to the evaluation criteria for chemotherapeutics for malignant skin carcinomas. Of the 15 patients, 11 (73.3%) achieved the objective response. Of the other four patients, three remained on treatment during study with stable disease and one showed disease progression. The median duration of stable disease was not reached but was 170 days or more (range, 29 to ≥253 days). As assessed according to the modified severity weighted assessment tool, nine patients (60.0%) achieved the objective response. The most common drug-related adverse event (AE) was influenza-like illness occurring in all patients enrolled, which did not lead to discontinuation of the study. Two serious AE were reported in two patients: aggravation of MF and aggravation of cataract, neither of which was considered directly related to the study drug. The patient with aggravation of MF died 50 days after the initiation of the study treatment. Another patient was withdrawn from the study due to drug-related cough, which disappeared after discontinuation of the drug. Overall, interferon-γ was effective and well-tolerated in Japanese patients with MF.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalJournal of Dermatology
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Mycosis Fungoides
Interferon-gamma
Interferons
Pharmaceutical Preparations
Skin
Drug-Related Side Effects and Adverse Reactions
Cough
Cataract
Human Influenza
Disease Progression
Japan
Carcinoma
Safety

Keywords

  • clinical trial
  • cutaneous T-cell lymphoma
  • i.v. drip
  • interferon-gamma
  • mycosis fungoides

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Sugaya, M., Tokura, Y., Hamada, T., Tsuboi, R., Moroi, Y., Nakahara, T., ... Iwatsuki, K. (2014). Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. Journal of Dermatology, 41(1), 50-56. https://doi.org/10.1111/1346-8138.12341

Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. / Sugaya, Makoto; Tokura, Yoshiki; Hamada, Toshihisa; Tsuboi, Ryoji; Moroi, Yoichi; Nakahara, Takeshi; Amano, Masahiro; Ishida, Syuichi; Watanabe, Daisuke; Tani, Mamori; Ihn, Hironobu; Aoi, Jun; Iwatsuki, Keiji.

In: Journal of Dermatology, Vol. 41, No. 1, 01.2014, p. 50-56.

Research output: Contribution to journalArticle

Sugaya, M, Tokura, Y, Hamada, T, Tsuboi, R, Moroi, Y, Nakahara, T, Amano, M, Ishida, S, Watanabe, D, Tani, M, Ihn, H, Aoi, J & Iwatsuki, K 2014, 'Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides', Journal of Dermatology, vol. 41, no. 1, pp. 50-56. https://doi.org/10.1111/1346-8138.12341
Sugaya, Makoto ; Tokura, Yoshiki ; Hamada, Toshihisa ; Tsuboi, Ryoji ; Moroi, Yoichi ; Nakahara, Takeshi ; Amano, Masahiro ; Ishida, Syuichi ; Watanabe, Daisuke ; Tani, Mamori ; Ihn, Hironobu ; Aoi, Jun ; Iwatsuki, Keiji. / Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. In: Journal of Dermatology. 2014 ; Vol. 41, No. 1. pp. 50-56.
@article{3d663879643244a49a1756df6a551078,
title = "Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides",
abstract = "A multisite, open-label, non-randomized, single-arm phase II study was conducted to evaluate the efficacy and safety profiles of interferon-γ in Japanese patients diagnosed with stage IA-IIIA mycosis fungoides (MF). Interferon-γ was administrated i.v. to 15 patients at a dose of 2 million Japan reference units once daily over 5 days a week for the first 4 weeks, followed by subsequent intermittent injection. The primary efficacy end-point was the overall skin response during the study as assessed according to the evaluation criteria for chemotherapeutics for malignant skin carcinomas. Of the 15 patients, 11 (73.3{\%}) achieved the objective response. Of the other four patients, three remained on treatment during study with stable disease and one showed disease progression. The median duration of stable disease was not reached but was 170 days or more (range, 29 to ≥253 days). As assessed according to the modified severity weighted assessment tool, nine patients (60.0{\%}) achieved the objective response. The most common drug-related adverse event (AE) was influenza-like illness occurring in all patients enrolled, which did not lead to discontinuation of the study. Two serious AE were reported in two patients: aggravation of MF and aggravation of cataract, neither of which was considered directly related to the study drug. The patient with aggravation of MF died 50 days after the initiation of the study treatment. Another patient was withdrawn from the study due to drug-related cough, which disappeared after discontinuation of the drug. Overall, interferon-γ was effective and well-tolerated in Japanese patients with MF.",
keywords = "clinical trial, cutaneous T-cell lymphoma, i.v. drip, interferon-gamma, mycosis fungoides",
author = "Makoto Sugaya and Yoshiki Tokura and Toshihisa Hamada and Ryoji Tsuboi and Yoichi Moroi and Takeshi Nakahara and Masahiro Amano and Syuichi Ishida and Daisuke Watanabe and Mamori Tani and Hironobu Ihn and Jun Aoi and Keiji Iwatsuki",
year = "2014",
month = "1",
doi = "10.1111/1346-8138.12341",
language = "English",
volume = "41",
pages = "50--56",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides

AU - Sugaya, Makoto

AU - Tokura, Yoshiki

AU - Hamada, Toshihisa

AU - Tsuboi, Ryoji

AU - Moroi, Yoichi

AU - Nakahara, Takeshi

AU - Amano, Masahiro

AU - Ishida, Syuichi

AU - Watanabe, Daisuke

AU - Tani, Mamori

AU - Ihn, Hironobu

AU - Aoi, Jun

AU - Iwatsuki, Keiji

PY - 2014/1

Y1 - 2014/1

N2 - A multisite, open-label, non-randomized, single-arm phase II study was conducted to evaluate the efficacy and safety profiles of interferon-γ in Japanese patients diagnosed with stage IA-IIIA mycosis fungoides (MF). Interferon-γ was administrated i.v. to 15 patients at a dose of 2 million Japan reference units once daily over 5 days a week for the first 4 weeks, followed by subsequent intermittent injection. The primary efficacy end-point was the overall skin response during the study as assessed according to the evaluation criteria for chemotherapeutics for malignant skin carcinomas. Of the 15 patients, 11 (73.3%) achieved the objective response. Of the other four patients, three remained on treatment during study with stable disease and one showed disease progression. The median duration of stable disease was not reached but was 170 days or more (range, 29 to ≥253 days). As assessed according to the modified severity weighted assessment tool, nine patients (60.0%) achieved the objective response. The most common drug-related adverse event (AE) was influenza-like illness occurring in all patients enrolled, which did not lead to discontinuation of the study. Two serious AE were reported in two patients: aggravation of MF and aggravation of cataract, neither of which was considered directly related to the study drug. The patient with aggravation of MF died 50 days after the initiation of the study treatment. Another patient was withdrawn from the study due to drug-related cough, which disappeared after discontinuation of the drug. Overall, interferon-γ was effective and well-tolerated in Japanese patients with MF.

AB - A multisite, open-label, non-randomized, single-arm phase II study was conducted to evaluate the efficacy and safety profiles of interferon-γ in Japanese patients diagnosed with stage IA-IIIA mycosis fungoides (MF). Interferon-γ was administrated i.v. to 15 patients at a dose of 2 million Japan reference units once daily over 5 days a week for the first 4 weeks, followed by subsequent intermittent injection. The primary efficacy end-point was the overall skin response during the study as assessed according to the evaluation criteria for chemotherapeutics for malignant skin carcinomas. Of the 15 patients, 11 (73.3%) achieved the objective response. Of the other four patients, three remained on treatment during study with stable disease and one showed disease progression. The median duration of stable disease was not reached but was 170 days or more (range, 29 to ≥253 days). As assessed according to the modified severity weighted assessment tool, nine patients (60.0%) achieved the objective response. The most common drug-related adverse event (AE) was influenza-like illness occurring in all patients enrolled, which did not lead to discontinuation of the study. Two serious AE were reported in two patients: aggravation of MF and aggravation of cataract, neither of which was considered directly related to the study drug. The patient with aggravation of MF died 50 days after the initiation of the study treatment. Another patient was withdrawn from the study due to drug-related cough, which disappeared after discontinuation of the drug. Overall, interferon-γ was effective and well-tolerated in Japanese patients with MF.

KW - clinical trial

KW - cutaneous T-cell lymphoma

KW - i.v. drip

KW - interferon-gamma

KW - mycosis fungoides

UR - http://www.scopus.com/inward/record.url?scp=84892783387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892783387&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.12341

DO - 10.1111/1346-8138.12341

M3 - Article

C2 - 24354781

AN - SCOPUS:84892783387

VL - 41

SP - 50

EP - 56

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 1

ER -